Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Fundamental Analysis

NASDAQ:XENE - Nasdaq - CA98420N1050 - Common Stock - Currency: USD

32.22  +0.1 (+0.31%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XENE. XENE was compared to 558 industry peers in the Biotechnology industry. XENE has a great financial health rating, but its profitability evaluates not so good. XENE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XENE has reported negative net income.
In the past year XENE has reported a negative cash flow from operations.
In the past 5 years XENE always reported negative net income.
In the past 5 years XENE always reported negative operating cash flow.
XENE Yearly Net Income VS EBIT VS OCF VS FCFXENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

XENE has a Return On Assets of -33.83%. This is in the better half of the industry: XENE outperforms 62.72% of its industry peers.
With a decent Return On Equity value of -35.72%, XENE is doing good in the industry, outperforming 73.48% of the companies in the same industry.
Industry RankSector Rank
ROA -33.83%
ROE -35.72%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
XENE Yearly ROA, ROE, ROICXENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

XENE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENE Yearly Profit, Operating, Gross MarginsXENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, XENE has more shares outstanding
XENE has more shares outstanding than it did 5 years ago.
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XENE Yearly Shares OutstandingXENE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XENE Yearly Total Debt VS Total AssetsXENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

XENE has an Altman-Z score of 35.36. This indicates that XENE is financially healthy and has little risk of bankruptcy at the moment.
XENE has a better Altman-Z score (35.36) than 97.13% of its industry peers.
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 35.36
ROIC/WACCN/A
WACCN/A
XENE Yearly LT Debt VS Equity VS FCFXENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 17.66 indicates that XENE has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.66, XENE belongs to the best of the industry, outperforming 91.22% of the companies in the same industry.
XENE has a Quick Ratio of 17.66. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XENE (17.66) is better than 91.22% of its industry peers.
Industry RankSector Rank
Current Ratio 17.66
Quick Ratio 17.66
XENE Yearly Current Assets VS Current LiabilitesXENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for XENE have decreased strongly by -19.19% in the last year.
EPS 1Y (TTM)-19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

XENE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.22% yearly.
XENE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 375.23% yearly.
EPS Next Y-35.69%
EPS Next 2Y-21.83%
EPS Next 3Y-14.01%
EPS Next 5Y12.22%
Revenue Next Year2279.98%
Revenue Next 2Y817.51%
Revenue Next 3Y587.06%
Revenue Next 5Y375.23%

3.3 Evolution

XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XENE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENE Price Earnings VS Forward Price EarningsXENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XENE Per share dataXENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

XENE's earnings are expected to decrease with -14.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.83%
EPS Next 3Y-14.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XENE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENON PHARMACEUTICALS INC

NASDAQ:XENE (7/18/2025, 12:06:09 PM)

32.22

+0.1 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners101.86%
Inst Owner Change0%
Ins Owners0.11%
Ins Owner Change0.84%
Market Cap2.47B
Analysts87.2
Price Target55.97 (73.71%)
Short Float %9.8%
Short Ratio5.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.53%
Min EPS beat(2)4.31%
Max EPS beat(2)10.75%
EPS beat(4)3
Avg EPS beat(4)3.14%
Min EPS beat(4)-5.1%
Max EPS beat(4)10.75%
EPS beat(8)6
Avg EPS beat(8)5.59%
EPS beat(12)8
Avg EPS beat(12)2.5%
EPS beat(16)10
Avg EPS beat(16)1.37%
Revenue beat(2)1
Avg Revenue beat(2)232.15%
Min Revenue beat(2)-100%
Max Revenue beat(2)564.3%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.23%
PT rev (3m)-4.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.07%
EPS NY rev (1m)0.24%
EPS NY rev (3m)1.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)275%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 329.63
P/FCF N/A
P/OCF N/A
P/B 3.51
P/tB 3.51
EV/EBITDA N/A
EPS(TTM)-3.23
EYN/A
EPS(NY)-4.48
Fwd EYN/A
FCF(TTM)-2.64
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0.1
BVpS9.17
TBVpS9.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.83%
ROE -35.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.83%
Cap/Sales 39.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.66
Quick Ratio 17.66
Altman-Z 35.36
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)190.35%
Cap/Depr(5y)241.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.87%
EPS Next Y-35.69%
EPS Next 2Y-21.83%
EPS Next 3Y-14.01%
EPS Next 5Y12.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year2279.98%
Revenue Next 2Y817.51%
Revenue Next 3Y587.06%
Revenue Next 5Y375.23%
EBIT growth 1Y-30.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.21%
EBIT Next 3Y-5.9%
EBIT Next 5Y12.25%
FCF growth 1Y-69.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.69%
OCF growth 3YN/A
OCF growth 5YN/A